Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
341-360 of 3,900 trials

Wilms Tumor: Metronomic Chemotherapy Study

We are evaluating a new chemotherapy regimen for children and teenagers with relapsed or refractory Wilms tumor. The study aims to assess safety, effectiveness, and quality of life during treatment.

Wilms Tumor6-12 monthsEfficacy phase (II)No PlaceboStandard MedicinesOncologyPediatrics

Advanced Ovarian Cancer: New Chemotherapy Approach

We are investigating a combined chemotherapy treatment for patients with advanced ovarian cancer after surgery. The study aims to assess its safety, effectiveness, and impact on quality of life.

Ovarian Cancer>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesGynecology and ObstetricsOncology

Mifepristone as a Weekly Contraceptive

We are studying the effectiveness and safety of a weekly dose of mifepristone for contraception. This trial also looks at how well patients accept this method and any potential effects on liver function.

Oral Contraception1-2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteGynecology and Obstetrics

Alopecia Areata: Baricitinib for Children

We are studying whether Baricitinib helps children aged 6 to under 18 with Alopecia Areata by comparing it to a placebo. This trial aims to find out if the medication can improve hair regrowth.

Alopecia Areata6-12 monthsConfirmation phase (III)16-20 visitsStandard MedicinesDermatologyPediatrics

Neuroendocrine Tumors: SAUNA Trial on Somatostatin Analogues

We are studying whether continuing or stopping somatostatin analogues affects survival and quality of life in patients with neuroendocrine tumors after disease progression. This trial aims to provide insights into the best treatment strategies for these patients.

Neuroendocrine Tumors1-2 yearsMonitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementGastroenterologyOncology

Early-Stage Breast Cancer: Long-Term Follow-Up Study

We are examining the long-term health of early-stage breast cancer patients from previous studies. This research will help us understand relapse rates and overall survival.

Early Stage Invasive Breast Cancer3-6 monthsMonitoring phase (IV)No PlaceboStandard MedicinesOncology

Preeclampsia Intervention 4: Metformin for Preterm Preeclampsia

We are studying whether daily metformin can help prolong pregnancy in women with preterm preeclampsia. We also want to see if it improves outcomes for newborns, like increasing birth weight and reducing time in neonatal care.

Preeclampsia>2 yearsConfirmation phase (III)Standard MedicinesGynecology and ObstetricsInternal Medicine

Advanced Solid Tumors: INCB099280 Study

We are testing a new medication for patients with advanced solid tumors who have not yet received immune checkpoint inhibitors. The goal is to evaluate its safety and how well it may control the disease.

Advanced Non-Small Cell Lung CancerAdvanced MelanomaUrothelial Carcinoma1-2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementInternal MedicineOncology

Advanced Melanoma: Tebentafusp Treatment Study

We are studying a new treatment for advanced melanoma in patients who have already been treated. This trial compares tebentafusp alone and with pembrolizumab against standard treatment options to see if it improves survival and quality of life.

Uveal MelanomaMetastatic Malignant MelanomaPreviously Treated Non-Ocular Advanced MelanomaEfficacy phase (II)Confirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementOncology

Head and Neck Cancer: New Imaging Technique

We are testing a new near-infrared imaging method to help surgeons detect remaining cancer cells during surgery. This study aims to improve the accuracy of tumor removal and preserve healthy tissue.

Head and Neck Cancer>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesOncologyOtolaryngology

Dermatomyositis and Polymyositis: PF-06823859 Study

We are testing a new medication to see if it helps reduce muscle and skin symptoms in adults with active dermatomyositis or polymyositis. This study compares the new treatment to a placebo to evaluate its effectiveness.

Polymyositis and DermatomyositisConfirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteInternal MedicineRheumatology

Rituximab for Amyotrophic Lateral Sclerosis (ALS)

We are studying whether adding Rituximab to standard treatment can slow symptom progression in ALS patients. The trial also monitors safety and various health indicators.

Sporadic Amyotrophic Lateral Sclerosis>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesNeurology

Endometrial Cancer: Durvalumab with Chemotherapy

We are studying a new treatment combining durvalumab with standard chemotherapy for patients with advanced or recurrent endometrial cancer. The goal is to see if this approach improves survival and quality of life compared to chemotherapy alone.

Endometrial Cancer>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteGynecology and ObstetricsOncology

Laryngeal Cancer: ELOS Study on New Treatment

We are studying whether adding pembrolizumab to standard chemotherapy and radiation helps patients with advanced laryngeal cancer avoid laryngectomy. This trial also examines the impact on swallowing quality and overall survival.

Advanced Laryngeal and Hypopharyngeal Cancer>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesOncology

Stage III Lung Cancer: MK-7684A Treatment Study

We are studying a new treatment combining MK-7684A with radiation and chemotherapy for patients with unresectable Stage III lung cancer. This trial compares it to standard treatment followed by Durvalumab.

Non-small cell lung cancer≤3 monthsConfirmation phase (III)Monitoring phase (IV)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementInternal MedicineOncology

Cancer Study: LY3537982 for KRAS G12C Mutant Tumors

We are testing a new drug, LY3537982, in patients with advanced solid tumors that have a specific genetic mutation. The goal is to see how well it works and how safe it is when used alone or with other cancer treatments.

KRAS G12C-Mutant Advanced Solid TumorsSafety phase (I)Efficacy phase (II)≤5 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesOncology

Advanced Solid Tumors: ADU-1805 Treatment Study

We are testing a new treatment called ADU-1805 for adults with advanced solid tumors. The study aims to evaluate its safety and how the body handles the medication.

Advanced Cancer1-2 yearsSafety phase (I)Oncology

Advanced Cancer: AZD8205 Treatment Study

We are studying the safety and early effectiveness of AZD8205, both alone and with other cancer treatments, for people with advanced or metastatic solid tumors. This research aims to find the best dose and understand how the drug works in the body.

Breast CancerOvarian CancerEndometrial CancerSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Gastroesophageal Reflux Disease in Infants: Diet vs. Medication

We are studying whether a cow's milk-free diet or a medication helps reduce reflux episodes in infants with GERD. Parents will track their baby's symptoms using an app during the trial.

Gastroesophageal Reflux Disease (GERD)Cows' Milk AllergyConfirmation phase (III)Monitoring phase (IV)Investigational MedicinesGastroenterologyPediatrics

Follicular Lymphoma: Radiotherapy with Obinutuzumab

We are studying whether adding Obinutuzumab to local radiotherapy improves outcomes for patients with early-stage Follicular Lymphoma. This trial will help us understand the effectiveness and safety of this combination treatment.

Early Stage Follicular Lymphoma3-6 monthsConfirmation phase (III)No PlaceboStandard MedicinesOncology